Intrinsiqs

Is Crescent Biopharma, Inc. overvalued?

Crescent Biopharma, Inc. (CBIO) — key valuation metrics and fundamentals.

No verdict
Price
$14.15
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$525.6M
Dividend yield
0.0%
Return on equity
-97.8%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CBIO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.